✦ LIBER ✦

PCN31 A COST MINIMISATION ANALYSIS OF NAVELBINE-CISPLATIN VERSUS GEMCITABINE-CISPLATIN IN ADVANCED NONSMALL CELL LUNG CANCER IN POLAND

✍ Scribed by A Skowron; S Polak; J Brandys

Book ID: 119594357
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 74 KB
Volume: 9
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)63461-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-minimisation analysis comparing gem

Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy

✍ Novello, S.; Kielhorn, A.; Stynes, G.; Selvaggi, G.; De Marinis, F.; Maestri, A. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 177 KB

27 Gemcitabine plus cisplatin versus eto

27 Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer: A randomized trial by the Spanish lung cancer group

✍ López Cabrerizo, M.P.; Cardenal, F.; Artal, A.; Lomas, M.; Alberola, V.; Massuti 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 128 KB

Cisplatin-gemcitabine-vinorelbine (PGV)

Cisplatin-gemcitabine-vinorelbine (PGV) vs cisplatin-vinorelbine (PV) vs cisplatin-gemcitabine (PG) in advanced non-small cell lung cancer (NSCLC). Interim analysis of a SICOG phase III trial

✍ P. Comella; N. Panza; G.P. Nicolella; L. Manzione; V. Lorusso; R. Cioffi; G. Dec 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 146 KB

Cisplatin-gemcitabine, vs. cisplatin-gem

Cisplatin-gemcitabine, vs. cisplatin-gemcitabine-vinorelbine, vs. cisplatin-gemcitabine-paclitaxel in advanced non-small-cell lung cancer. First-stage analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial

✍ Comella, P; Frasci, G; Panza, N; Nicolella, G; Manzione, L; De Cataldis, G; Ciof 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Phase III trial of gemcitabine and carbo

Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma

✍ Sarah Danson; Mark R. Middleton; Kenneth J. O'Byrne; Mark Clemons; Malcolm Ranso 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB

## Abstract ## BACKGROUND The authors compared gemcitabine and carboplatin (GC) with mitomycin, ifosfamide, and cisplatin (MIC) or mitomycin, vinblastine, and cisplatin (MVP) in patients with advanced nonsmall cell lung carcinoma (NSCLC). The primary objective was survival. Secondary objectives we

PCN89 A COST EFFECTIVENESS ANALYSIS DEMO

PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN

✍ J de Castro Carpeño; A Castro Gómez; S Walzer 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB